Cinoxacin is a new synthetic compound similar chemically and in antimicrobial activity to oxolonic acid and nalidixic acid. It is most effective against Escherichia coli and Proteus mirabilis, but at concentrations expected in the urine it is inhibitory for all species of Enterobacteriaceae. Relative to nalidixic acid, cinoxacin has slightly greater inhibitory and bactericidal activity, less inoculum effect probably due to less heterogeneity in the susceptibility of bacterial cells, and less inhibition by high concentrations of serum protein. Both drugs are more active in an acid than an alkaline medium. Glucose can specifically antagonize the inhibitory effect against P. mirabilis. In urine the bactericidal rate and effect are decreased. Resistance to cinoxacin can be developed quickly by serial.transfers in vitro. Some nonresistant organisms remained viable in bactericidal drug concentrations. The in vivo importance of the favorable features of cinoxacin must be determined by clinical trials.
line (1-2 benzodiozine). Chemically, the compound is 1-ethyl-1,4-dihydro-4-oxo-(1,3)-dioxolo-(4,5-g)cinnoline-3-carboxylic acid. Cinoxacin belongs to the same class of antimicrobial drugs as nalidixic acid and oxolinic acid which are used in the treatment of urinary tract infections. Its antibacterial activity is similar to these drugs in vitro and perhaps superior in vivo against experimental pyelonephritis in rats (1, 5) . In this study a series of observations were made to further evaluate the antimicrobial action of cinoxacin against recent clinical isolates and compare its activity with nalidixic acid.
MATERIALS AND METHODS
Recent bacterial isolates (170) from patients at the University of Illinois Hospital were studied. Cinoxacin was provided by the Lilly Research Laboratories (compound 64716) and nalidixic acid by Sterling Winthrop Research Institute. Stock solutions of 2,000 Ag of each drug per ml were prepared in phosphate buffer (pH 7), stored at -20 C, and used within 6 weeks. Minimal inhibitory concentrations (MIC) for cinoxacin and nalidixic acid were determined by the standard tube dilution or microtiter technique. The basic medium was tryptose phosphate broth which was modified for specific tests by adjustment of pH, or by the addition of defined amounts of horse serum, sodium chloride, sucrose, dextrose, or urea. Urine that was used as a bacteriologic medium was obtained from healthy adults, pooled, and filtered through a sterilizing filter. Serial twofold dilutions of drug standards were made in tryptose phosphate broth, yielding drug concentrations from 500 to 0.25 gg/ml. The standard bacterial inoculum was a 1:1,000 dilution of a log-phase bacterial culture, yielding a final concentration of approximately 106 bacteria per ml. The MIC end point was determined by visual turbidity after 16 to 18 h of incubation at 37 C. Most of the strains tested by the broth dilution methods were retested by the agar disk diffusion method using 30 ,ig disks of each drug.
The minimal bactericidal concentration (MBC) was determined from the clear tubes in the sensitivity test by quantitative subculture onto semisolid media. The MBC end point was designated as that concentration of antibiotic that produced a reduction in viable organisms of at least 4 logs or 99.99%. Bactericidal rates were determined by counting the number of viable bacteria at different intervals after incubation in various drug concentrations. The drug carryover effect was reduced by dilutions in broth and use of alkaline medium.
Two strains of drug-susceptible Escherichia coli were serially passed in subinhibitory concentrations of cinoxacin and nalidixic acid. The strains were transferred 11 times using as inoculum the organism growing in the highest concentration of drug. To detect single-step-resistant mutants, a large inoculum of organisms was incubated in tryptose phosphate broth containing 100, 200, or 400 times the MIC of either antibiotic.
A strain of E. coli made resistant to cinoxacin in the laboratory (MIC = 1,000 jAg/ml) was used as the donor strain in the attempted transfer of resistance to a recipient strain of E. coli K-12, which was susceptible to cinoxacin but able to grow in sodium azide.
RESULTS
Of the 170 different bacterial strains tested for susceptibility to cinoxacin, the cumulative percentage of each species inhibited by increasing concentrations is shown in Fig. 1 . Proteus mirabilis and E. coli were the most susceptible 'species and, as shown by the steepness of the slopes, different strains were quite uniform in their susceptibility. These species had the smallest difference in the range of inhibition (MIC = 0.5 to 32 tg/ml). In contrast, indolepositive strains of Proteus bacilli, Klebsiella sp., Citrobacter sp., and Serratia sp. were nonuniform in the susceptibility of the different strains which had a range of inhibitory concentrations from 1 to 250,ug/ml. However, between 50 and 70% of the strains of these species were inhibited by 8 ,jg/ml. In contrast all strains of Pseudomonas aeruginosa were resistant to >250 /g/ml and staphylococci and enterococci were inhibited only at relatively high concentrations of cinoxacin, 32 to 250 ,g/ml.
The relation between the MIC in broth and the zone size in the agar diffusion sensitivity tests using a 30-,ug disk were analyzed. The results using cinoxacin and nalidixic acid were comparable. Although a general correlation was observed, the variation in zone size at each level of susceptibility was quite great. If 8 ,ug/ml were designated as an inhibitory level for susceptible strains, only those with a zone size of 25 mm or more could reliably be considered susceptible. This would fail to identify a few susceptible strains of Proteus and Klebsiella (about 10%) and improperly include some resistant strains (about 20%), especially those of the KlebsiellaEnterobacter group. If urinary concentrations of cinoxacin (200 to 500 gg/ml) (2) were considered as the basis for susceptibility (3, 4) any zone around a 30 u-g disk would indicate a susceptible strain.
Data on the bactericidal activity of cinoxacin against gram-negative bacilli are shown in Table 1 and compared to nalidixic acid. On the basis of the end point for 50% of the strains, cinoxacin was generally more effective than nalidixic acid. The minimal concentration required to kill 90% of strains among E. coli, indole-positive Proteus bacilli, and P. mirabilis was significantly lower for cinoxacin than nalidixic acid. The influence of the inoculum size in determining susceptibility to cinoxacin and nalidixic acid is shown in Table 2 . As the inoculum of E. coli was increased from 101 to 107 bacteria per ml, the MIC to cinoxacin increased eightfold. With nalidixic acid under the same conditions the MIC increased 32-fold. A similar result was observed using a susceptible strain of P. mirabilis suggesting less heterogeneity in the susceptibility of cells to cinoxacin than nalidixic acid.
The effect of the pH of the medium on the bacterial inhibition by cinoxacin and nalidixic acid is shown in the upper portion of Fig. 2 . Increasing alkalinity decreased the susceptibility of all species of gram-negative bacilli tested. With nalidixic acid, the critical pH range appeared to be narrower for E. coli and P. mirabilis, but otherwise the changes were similar to those observed with cinoxacin.
The effect of the serum concentration of the medium is shown in the lower panels of Fig. 2 . Increasing the amount of serum from 0 to 75% had essentially no effect on the antibacterial activity of cinoxacin but a directly related fourto eightfold increase in the MIC of strains to nalidixic acid. VOL. 7, 1975 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from An unknown factor(s) in normal human urine at neutral pH was also antagonistic to the killing effect of both cinoxacin and nalidixic acid. In Fig. 3 The rate of bacterial killing was also decreased in urine. Both an early and a sustained decrease in the rate of killing in urine was observed for both species. It was not overcome by the high concentration of drug in excess of the MBC. In urine there was also a less rapid and lower replication rate of bacteria relative to broth which could be the cause of the slower killing rate.
The development of resistance of E. coli to cinoxacin or nalidixic acid occurred rapidly through multiple obligatory steps with serial transfers in the presence of subinhibitory concentrations of drug. The data are given in Table  4 . In twelve passages there was a 1,000-fold increase in the MIC. No single-step mutants with facultative resistance were identified in the specimens studied. The induced resistance was non-transferable as an R-factor.
DISCUSSION
The in vitro antibacterial activity of cinoxacin is readily demonstrable against all of the species tested with the exception of P. aeruginosa. With that exclusion gram-negative bacilli are much more susceptible than grampositive cocci. The activity of the drug closely resembles that of nalidixic acid (2a, 5) . Only strains of E. coli and P. mirabilis may be appreciably more susceptible to cinoxacin. In this respect it is more like oxolinic acid which cinoxacin also resembles closely chemically. The differences in antimicrobial activity observed in vitro may not be apparent in the treatment of urinary tract infections because at concentrations expected to be achieved in the urine (250 to 500 jig/ml) ( The demonstration of susceptible bacterial persistors suggests that the bactericidal effect of cinoxacin requires bacterial replication. The effect is probably exerted by alterations in DNA metabolism as it is with nalidixic acid. The general cross-resistance between these two drugs may mean that the site of action is also nearly the same. The antagonistic effect of glucose with P. mirabilis and the demonstration of drug antagonistic factor(s) in human urine indicate that there are species differences and species-specific drug inhibitors. Several of these factors, including pH related activity, glucose antagonism (P. mirabilis), variations in strain susceptibility, metabolic persistors, the requirement for replication, possible biologic antagonists in urine and tissues, and the ease of selection and emergence of resistant clones, forbode difficulties in the successful treatment of patients with chronic and complicated urinary tract infections. However, cinoxacin appears to have some advantages over nalidixic acid on the basis of these in vitro observations and evaluation of the in vivo importance of the various factors will need to be made from clinical trials.
